-
Bill & Melinda Gates Foundation Invests $17 Million in CanSino Biologics’ Recombinant Polio Vaccine
•
The Bill & Melinda Gates Foundation has committed USD 17 million to support the development of CS-2036, a recombinant polio vaccine, by China-based CanSino Biologics (SHA: 688185, HKG: 6185). The investment will fund various development efforts, including clinical trials, process development, scaling-up, and the development of a candidate combined vaccine…
-
CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine
•
CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of its first patient in a Phase I clinical study for its recombinant polio vaccine in Australia. This candidate vaccine is a non-infectious virus-like particle (VLP) formulation, developed utilizing CanSino’s proprietary protein structure design and VLP…
-
Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge
•
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs) for their COVID-19 vaccines targeting the Omicron XBB variant. Among the notable developments are Lizhu Pharmaceutical’s (HKG: 1513) recombinant bivalent vaccine, which combines the prototype strain with the Omicron XBB variant, and CanSino Biologics’ (SHA:…
-
Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development
•
The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to support the development of CS-2036, a recombinant polio vaccine by China-based CanSino Biologics (SHA: 688185, HKG: 6185). This investment underscores the foundation’s dedication to global health initiatives and the eradication of polio. Innovative Approach to…
-
CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first half of 2023, recording revenues of RMB 21.09 million (USD 2.89 million), a decrease of 96.7% year-on-year (YOY). The contributions from China and overseas markets were RMB 17.93 million and RMB 3.16 million, respectively. The…
